Payment overview · 2025
General Payments
$980.42
50 reported records · 14 companies
Healthcare provider profile · identity verified
Jennifer Miley, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PENSACOLA, FL · NPI 1154338424
Verified facts
What the public records show
CMS Open Payments records show Jennifer Miley, M.D. received $980.42 in general payments during 2025 across 50 reported records.
ABBVIE INC. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $184.04 | 18.8% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $161.56 | 16.5% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $149.00 | 15.2% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $135.36 | 13.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $52.72 | 5.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.46 | 5.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.96 | 4.6% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $42.70 | 4.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.24 | 4.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.42 | 3.2% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $24.93 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.80 | 2.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.98 | 2.3% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.25 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $980.42 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $135.36 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $131.95 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $120.14 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $102.46 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $77.97 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.98 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $52.72 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.46 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.46 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.80 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $44.96 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $42.70 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.24 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.78 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.61 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.61 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.61 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.86 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.86 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.98 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $15.09 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 119 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 106 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 46 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
106 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 564 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 419 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 359 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 305 | 99 |
| Lisinopril | Lisinopril | 305 | 107 |
| Hydrochlorothiazide | Hydrochlorothiazide | 265 | 98 |
| Omeprazole | Omeprazole | 264 | 95 |
| Losartan Potassium | Losartan Potassium | 257 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 67 |
| Trazodone Hcl | Trazodone Hcl | 209 | 61 |
| Gabapentin | Gabapentin | 207 | 81 |
| Metformin Hcl | Metformin Hcl | 185 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 174 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 50 |
| Alprazolam | Alprazolam | 164 | 46 |
| Sertraline Hcl | Sertraline Hcl | 149 | 47 |
| Famotidine | Famotidine | 140 | 45 |
| Ozempic | Semaglutide | 136 | 30 |
| Montelukast Sodium | Montelukast Sodium | 127 | 37 |
| Furosemide | Furosemide | 120 | 51 |
| Eliquis | Apixaban | 119 | 26 |
| Potassium Chloride | Potassium Chloride | 116 | 45 |
| Carvedilol | Carvedilol | 110 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 61 |
| Mounjaro | Tirzepatide | 106 | 29 |
| Tramadol Hcl | Tramadol Hcl | 102 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 52 |
| Metformin Hcl Er | Metformin Hcl | 95 | 28 |
| Simvastatin | Simvastatin | 94 | 31 |
| Topiramate | Topiramate | 84 | 37 |
| Estradiol | Estradiol | 82 | 32 |
| Meloxicam | Meloxicam | 81 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 34 |
| Bupropion Xl | Bupropion Hcl | 77 | 30 |
| Spironolactone | Spironolactone | 75 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 32 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 64 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 20 |
| Lamotrigine | Lamotrigine | 58 | 19 |
| Lorazepam | Lorazepam | 58 | 17 |
| Methylprednisolone | Methylprednisolone | 57 | 50 |
| Clonidine Hcl | Clonidine Hcl | 56 | 25 |
| Ezetimibe | Ezetimibe | 56 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 17 |
| Eszopiclone | Eszopiclone | 53 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 17 |
| Allopurinol | Allopurinol | 52 | 16 |
| Fenofibrate | Fenofibrate | 52 | 19 |
| Atenolol | Atenolol | 51 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 50 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 12 |
| Synthroid | Levothyroxine Sodium | 46 | 11 |
| Clonazepam | Clonazepam | 44 | 14 |
| Meclizine Hcl | Meclizine Hcl | 44 | 25 |
| Alendronate Sodium | Alendronate Sodium | 43 | 16 |
| Buspirone Hcl | Buspirone Hcl | 43 | 18 |
| Memantine Hcl | Memantine Hcl | 43 | 15 |
| Azelastine Hcl | Azelastine Hcl | 42 | 24 |
| Mirtazapine | Mirtazapine | 41 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 12 |
| Farxiga | Dapagliflozin Propanediol | 38 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 12 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 12 |
| Propranolol Hcl | Propranolol Hcl | 35 | 12 |
| Valacyclovir | Valacyclovir Hcl | 35 | 17 |
| Vilazodone Hcl | Vilazodone Hcl | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 13 |
| Methocarbamol | Methocarbamol | 32 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Prednisone | Prednisone | 28 | 12 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 17 |
| Doxepin Hcl | Doxepin Hcl | 26 | 11 |
| Cephalexin | Cephalexin | 25 | 23 |
| Solifenacin Succinate | Solifenacin Succinate | 25 | 15 |
| Ibuprofen | Ibuprofen | 24 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | 11 |
| Baclofen | Baclofen | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Zaleplon | Zaleplon | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Jardiance | Empagliflozin | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | 13 |
| Valsartan | Valsartan | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 12 |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $980.42 · 50 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, COMIRNATY, ELIQUIS, EVENITY, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, SPRAVATO, SYNTHROID, TRELEGY ELLIPTA, TRINTELLIX, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error